Testin is a tumor suppressor and prognostic marker in breast cancer

Cancer Science

Volumn 103, Issue 12, 2012, Pages 2092-2101

  Zhu, Jiang ^a   Li, Xiaoyan ^a   Kong, Xiangnan ^a   Moran, Meena S ^b   Su, Peng ^a   Haffty, Bruce G ^c   Yang, Qifeng ^a,d  

^a SHANDONG UNIVERSITY   (China)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^d Shandong University   (China)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE A; METHYLTESTOSTERONE; MICRORNA 29B; TUMOR MARKER;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; ATYPICAL DUCTAL HYPERPLASIA; BREAST CANCER; CANCER GROWTH; CANCER INHIBITION; CANCER INVASION; CANCER PROGNOSIS; CARCINOMA IN SITU; CELL PROLIFERATION; CONTROLLED STUDY; ECTOPIC HORMONE PRODUCTION; ENZYME INHIBITION; FEMALE; GENE EXPRESSION; GENE FUNCTION; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRADUCTAL CARCINOMA; LUNG METASTASIS; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; RNA INTERFERENCE; TISSUE MICROARRAY; TUMOR SUPPRESSOR GENE; TUMOR XENOGRAFT;

ANIMALS; BREAST; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CELL PROLIFERATION; CYTOSKELETAL PROTEINS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LIM DOMAIN PROTEINS; MICE; MICE, NUDE; NIH 3T3 CELLS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84870667328     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12020     Document Type: Article

References (24)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62: 10-29.
2. Tatarelli C, Linnenbach A, Mimori K, Croce CM. Characterization of the human TESTIN gene localized in the FRA7G region at 7q31.2. Genomics 2000; 68: 1-12.
3. Tobias ES, Hurlstone AF, MacKenzie E, McFarlane R, Black DM. The TES gene at 7q31.1 is methylated in tumours and encodes a novel growth-suppressing LIM domain protein. Oncogene 2001; 20: 2844-53.
4. Coutts AS, MacKenzie E, Griffith E, Black DM. TES is a novel focal adhesion protein with a role in cell spreading. J Cell Sci 2003; 116: 897-906.
5. Garvalov BK, Higgins TE, Sutherland JD et al. The conformational state of Tes regulates its zyxin-dependent recruitment to focal adhesions. J Cell Biol 2003; 161: 33-9.
6. Chene L, Giroud C, Desgrandchamps F et al. Extensive analysis of the 7q31 region in human prostate tumors supports TES as the best candidate tumor suppressor gene. Int J Cancer 2004; 111: 798-804.
7. Qiu H, Zhu J, Yuan C, Yan S, Yang Q, Kong B. Frequent hypermethylation and loss of heterozygosity of the testis derived transcript gene in ovarian cancer. Cancer Sci 2010; 101: 1255-60.
8. Mueller W, Nutt CL, Ehrich M et al. Downregulation of RUNX3 and TES by hypermethylation in glioblastoma. Oncogene 2007; 26: 583-93.
9. Griffith E, Coutts AS, Black DM. RNAi knockdown of the focal adhesion protein TES reveals its role in actin stress fibre organisation. Cell Motil Cytoskeleton 2005; 60: 140-52.
10. Drusco A, Zanesi N, Roldo C et al. Knockout mice reveal a tumor suppressor function for Testin. Proc Natl Acad Sci U S A 2005; 102: 10947-51.
11. Hu G, Chong RA, Yang Q et al. MTDH activation by 8q22 genomic gain promotes chemoresistance and metastasis of poor-prognosis breast cancer. Cancer Cell 2009; 15: 9-20.
12. Bouwman P, Aly A, Escandell JM et al. 53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers. Nat Struct Mol Biol 2010; 17: 688-95.
13. Yang QF, Sakurai T, Yoshimura G et al. Expression of Bcl-2 but not Bax or p53 correlates with in vitro resistance to a series of anticancer drugs in breast carcinoma. Breast Cancer Res Treat 2000; 61: 211-6.
14. Broustas CG, Ross JS, Yang Q et al. The proapoptotic molecule BLID interacts with Bcl-XL and its downregulation in breast cancer correlates with poor disease-free and overall survival. Clin Cancer Res 2010; 16: 2939-48.
15. Li X, Kong X, Huo Q et al. Metadherin enhances the invasiveness of breast cancer cells by inducing epithelial to mesenchymal transition. Cancer Sci 2011; 102: 1151-7.
16. Fang JH, Zhou HC, Zeng C et al. MicroRNA-29b suppresses tumor angiogenesis, invasion, and metastasis by regulating matrix metalloproteinase 2 expression. Hepatology 2011; 54: 1729-40.
17. Pratheeshkumar P, Kuttan G. Nomilin inhibits tumor-specific angiogenesis by downregulating VEGF, NO and proinflammatory cytokine profile and also by inhibiting the activation of MMP-2 and MMP-9. Eur J Pharmacol 2011; 668: 450-8.
18. Babykutty S, S PP, J NR et al. Nimbolide retards tumor cell migration, invasion, and angiogenesis by downregulating MMP-2/9 expression via inhibiting ERK1/2 and reducing DNA-binding activity of NF-kappaB in colon cancer cells. Mol Carcinog 2012; 51: 475-90.
19. Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 2010; 141: 52-67.
20. Muhlebach MD, Schaser T, Zimmermann M et al. Liver cancer protease activity profiles support therapeutic options with matrix metalloproteinase-activatable oncolytic measles virus. Cancer Res 2010; 70: 7620-9.
21. Sarti M, Sevignani C, Calin GA et al. Adenoviral transduction of TESTIN gene into breast and uterine cancer cell lines promotes apoptosis and tumor reduction in vivo. Clin Cancer Res 2005; 11: 806-13.
22. Weis SM, Cheresh DA. Tumor angiogenesis: molecular pathways and therapeutic targets. Nat Med 2011; 17: 1359-70.
23. Zerbini G, Lorenzi M, Palini A. Tumor angiogenesis. N Engl J Med 2008; 359: 763.; author reply 4.
24. Kerbel RS. Tumor angiogenesis. N Engl J Med 2008; 358: 2039-49.